TIM
INO icon

Tevis Investment Management’s Inovio Pharmaceuticals INO Stock Holding History

Tevis Investment Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-83
Closed -$2K – 440
2022
Q2 		$2K Hold
83
– – ﹤0.01% 456
2022
Q1 		$4K Hold
83
– – ﹤0.01% 448
2021
Q4 		$5K Buy
+83
New +$6.65K ﹤0.01% 486

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tevis Investment Management's INO Position: Q3 2022 in Review

Tevis Investment Management sold out of Inovio Pharmaceuticals (INO) in Q3 2022, closing a stake of 83 shares — an estimated $2K sold.

Tevis Investment Management first reported a position in INO in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q4 2021. 182 funds tracked by Wall St. Rank hold INO as of Q3 2022.

  • Tevis Investment Management reported no remaining Inovio Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Tevis Investment Management sold 83 Inovio Pharmaceuticals shares in Q3 2022, an estimated $2K.
  • Tevis Investment Management first reported a position in Inovio Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Tevis Investment Management's Inovio Pharmaceuticals position peaked at $5K in Q4 2021.
  • 182 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2022.

Based on Tevis Investment Management's 13F filing for Q3 2022, filed 7 Nov 2022.